NASDAQ: AMGN Investor Notice: Investigation over Possible Securities Laws Violations by Amgen Inc.
An investigation for investors in Amgen Inc. (NASDAQ: AMGN) shares over potential securities laws violations by Amgen Inc. was announced.
San Diego, CA -- (SBWire) -- 05/11/2022 --An investigation was announced for investors of Amgen Inc. (NASDAQ: AMGN) shares over potential securities laws violations by Amgen Inc.
Investors who purchased shares of Amgen Inc. (NASDAQ: AMGN), have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Amgen Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Thousand Oak, CA based Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. Amgen Inc. reported that its annual Total Revenue rose from over $25.42 billion in 2020 to over $25.97 billion in 2021, and that its Net Income declined from over $7.26 billion in 2020 to over $5.89 billion in 2021.
On April 27, 2022, Amgen Inc disclosed in its first quarter 2022 earnings release that "[o]n April 18, 2022, Amgen received a notice of deficiency from the [Internal Revenue Service ('IRS')] for the 2013-2015 period proposing adjustments primarily related to the allocation of profits between certain of the Company's entities in the United States and the U.S. territory of Puerto Rico" which "seeks to increase Amgen's U.S. taxable income for the 2013-2015 period by an amount that would result in additional federal tax of approximately $5.1 billion, plus interest." Amgen Inc also disclosed that the IRS "notice proposes penalties of approximately $2 billion."
Shares of Amgen Inc. (NASDAQ: AMGN) declined $258.39 per share on April 21, 2022, to $231.15 per share on April 28, 2022.
Those who purchased shares of Amgen Inc. (NASDAQ: AMGN) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
About The Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
Media Relations Contact
View this press release online at: http://rwire.com/1357461